Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Wave Life Sci Ord Sh (WVE)

Wave Life Sci Ord Sh (WVE)
6.57 -0.22 (-3.24%) 12:48 ET [NASDAQ]
6.56 x 287 6.59 x 41
Realtime by (Cboe BZX)
6.56 x 287 6.59 x 41
Realtime 6.72 -0.07 (-1.03%) 08:07 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
6.54
Day High
6.82
Open 6.68
Previous Close 6.79 6.79
Volume 253,533 253,533
Avg Vol 1,601,679 1,601,679
Stochastic %K 69.73% 69.73%
Weighted Alpha -33.92 -33.92
5-Day Change +0.67 (+11.32%) +0.67 (+11.32%)
52-Week Range 4.25 - 16.74 4.25 - 16.74
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,042,170
  • Shares Outstanding, K 153,486
  • Annual Sales, $ 108,300 K
  • Annual Income, $ -97,010 K
  • EBIT $ -110 M
  • EBITDA $ -102 M
  • 60-Month Beta -0.93
  • Price/Sales 9.62
  • Price/Cash Flow N/A
  • Price/Book 4.94

Options Overview Details

View History
  • Implied Volatility 98.17% ( -2.36%)
  • Historical Volatility 90.36%
  • IV Percentile 61%
  • IV Rank 40.01%
  • IV High 195.68% on 07/18/24
  • IV Low 33.14% on 05/20/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 336
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 2,509
  • Open Int (30-Day) 9,254

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.27
  • Number of Estimates 8
  • High Estimate -0.20
  • Low Estimate -0.30
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.28 +24.81%
on 04/09/25
Period Open: 9.44
10.91 -39.60%
on 03/26/25
-2.85 (-30.19%)
since 03/25/25
3-Month
5.28 +24.81%
on 04/09/25
Period Open: 12.01
12.52 -47.36%
on 02/05/25
-5.42 (-45.13%)
since 01/24/25
52-Week
4.25 +55.06%
on 06/27/24
Period Open: 4.74
16.74 -60.62%
on 11/11/24
+1.85 (+39.03%)
since 04/25/24

Most Recent Stories

More News
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

WVE : 6.57 (-3.24%)
Wave Life Sciences: Q4 Earnings Snapshot

Wave Life Sciences: Q4 Earnings Snapshot

WVE : 6.57 (-3.24%)
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

WVE : 6.57 (-3.24%)
Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

WVE : 6.57 (-3.24%)
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

WVE : 6.57 (-3.24%)
Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation

WVE : 6.57 (-3.24%)
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

WVE : 6.57 (-3.24%)
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

WVE : 6.57 (-3.24%)
Insider Sale: President and CEO of $WVE (WVE) Sells 50,000 Shares

PAUL BOLNO, the President and CEO of $WVE ($WVE), sold 50,000 shares of the company on 11-25-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 18.7% of their...

WVE : 6.57 (-3.24%)
Wave Life Sciences to Present at Upcoming Investor Conferences

WVE : 6.57 (-3.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1...

See More

Key Turning Points

3rd Resistance Point 7.34
2nd Resistance Point 7.13
1st Resistance Point 6.96
Last Price 6.57
1st Support Level 6.59
2nd Support Level 6.38
3rd Support Level 6.21

See More

52-Week High 16.74
Fibonacci 61.8% 11.97
Fibonacci 50% 10.49
Fibonacci 38.2% 9.02
Last Price 6.57
52-Week Low 4.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective